Safety14 min readAugust 8, 2026

Brand-Name vs Compounded GLP-1: What Changed in 2025, and What to Ask Before You Buy

Compounded semaglutide runs $99 to $299 a month. Wegovy runs $650 to $1,599. The gap is real and so is the reason for it: compounded drugs are not FDA-approved, and since both shortages resolved the legal basis for making them narrowed sharply. This is what the difference actually is.

By Med Consumer Watch Team

If you have shopped for GLP-1 treatment online, you have seen the same molecule at wildly different prices. Compounded semaglutide runs roughly $99 to $299 a month. Wegovy runs $650 to $1,599. Same active ingredient, ten-fold difference. The gap is not a scam and it is not a bargain. It is a different legal category of product, and the rules governing it changed materially in 2024 and 2025. Most of the marketing you will encounter has not caught up. Three things to understand before you choose. Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness or manufacturing quality before they reach you. A compounded preparation containing the same active ingredient as an approved drug is not a generic and has not been shown to be therapeutically equivalent. The shortage justification is gone. Tirzepatide came off the FDA shortage list in October 2024 and semaglutide in early 2025. Compounding these drugs can no longer rest on a shortage. The FDA is actively enforcing. In 2026 alone it issued warning letters to multiple GLP-1 telehealth sellers, including one to a provider we review, finding compounded semaglutide and tirzepatide misbranded. None of that means compounded GLP-1s are worthless or that people using them are being defrauded. It means the trade-off is real, and you should make it knowingly.

What the Two Things Actually Are

Brand-name GLP-1s — Wegovy and Ozempic (semaglutide, Novo Nordisk), Zepbound and Mounjaro (tirzepatide, Eli Lilly), Saxenda and Victoza (liraglutide) — are FDA-approved drugs. Approval means the manufacturer submitted clinical trial evidence of safety and effectiveness, the FDA reviewed it, and the manufacturing facility is subject to FDA inspection under current Good Manufacturing Practice rules. Every vial is made to a specification the agency has examined. Compounded GLP-1s are prepared by a pharmacy, not a drug manufacturer. Compounding is a legitimate, long-standing practice that exists so pharmacists can make a preparation an individual patient needs that is not commercially available — a different strength, a formulation without an allergen, a liquid for someone who cannot swallow a tablet. What compounding is not is a cheaper route to the same approved product. The FDA is explicit: compounded drugs are not FDA-approved, are not reviewed for safety, effectiveness or manufacturing quality before marketing, and a compounded version of an approved drug is not a generic equivalent of it. There are also two different kinds of compounding pharmacy, and the distinction matters more than most marketing admits:

503A pharmacies — traditional compounding. They prepare a medication for an individual patient pursuant to a specific prescription, regulated by state boards of pharmacy under USP standards. They are not FDA-registered facilities and do not compound in bulk.
503B outsourcing facilities — FDA-registered, subject to federal cGMP requirements and FDA inspection, and permitted to compound in bulk without individual prescriptions.
Most telehealth GLP-1 prescriptions are filled by 503A pharmacies, which is the less regulated of the two pathways.
Neither produces an FDA-approved drug. A 503B facility is inspected; its output is still not an approved product.

This is why we ask every provider we review to name the pharmacy that fills its prescriptions, and why we flag it as a negative when they will not. A named pharmacy can be looked up — you can check its state licensure, its 503A or 503B status, and whether it has an inspection or recall history. An unnamed one cannot be checked at all. Across the providers we have reviewed, refusal to name the pharmacy is the single most common transparency gap.

What Changed: The Shortage Rules

This is the part most buyers have not been told, and it is the reason the market looks different in 2026 than it did in 2023. During a declared shortage, federal law permits compounders to prepare copies of an approved drug that would otherwise be prohibited. Semaglutide and tirzepatide were both in shortage for an extended period, and an entire telehealth industry was built on that allowance. Both shortages have ended. The FDA removed tirzepatide from the shortage list in October 2024 and semaglutide in early 2025. What that means legally. With no shortage on the books, the "essentially a copy" rule applies again. A 503A pharmacy can no longer justify compounding semaglutide or tirzepatide by pointing to a shortage. Lawful patient-specific compounding now turns on a documented clinical reason for the individual patient — a dose that is not commercially available, a documented sensitivity to an excipient in the approved product, or a specific titration need that the commercial pen cannot meet. That is a substantially narrower basis than "there is a shortage," and it is a fair thing to ask your prescriber about directly. What it does not mean. It does not mean every compounded GLP-1 prescription is unlawful, and it does not mean patients currently taking one are doing something wrong. Legitimate patient-specific compounding continues. What ended is the blanket justification.

Be alert to providers still citing shortages as their rationale. In reviewing telehealth GLP-1 providers we have found sites in 2026 still explaining their compounded offerings by reference to "high demand and national shortages" — a regulatory situation that ended between eighteen months and two years ago. Rixa Health is one example we documented. A provider whose stated legal basis is out of date is telling you something about how closely it is tracking the rules it operates under.

The question to ask, in writing: "Now that the shortages have resolved, what is the individual clinical basis for compounding this medication for me?" A good provider will have an answer — a dose not commercially available, a documented excipient issue. A provider that responds with marketing language, or does not respond, has answered a different and more useful question.

The 2026 Enforcement Record

The FDA has not been passive about how these products are marketed. Our reviews have documented several actions, all from primary sources. Ivím Health — the FDA issued warning letter 721816 on February 20, 2026 to Ivim Services LLC. After reviewing the company's website in December 2025, the agency concluded that false or misleading claims violated FDCA sections 502(a) and 502(bb), that its compounded semaglutide and tirzepatide are therefore misbranded, and that introducing them into interstate commerce violated section 301(a). See our Ivím Health review. FITISH — warning letter 728280, June 8, 2026. Medica Weight Loss — warning letter 728284, June 8, 2026. Koi CBD — a separate but instructive case from the adjacent hemp market: warning letter 651252, July 18, 2023, finding delta-8 gummies adulterated for containing an unsafe food additive. See our Koi CBD review. What these letters are, and are not. Section 502(a) concerns false or misleading labelling. Section 502(bb) concerns compounded drugs that are essentially copies of approved products. These are marketing and labelling actions — they are not findings that anyone was harmed, that products were contaminated, or that potency was wrong. They still matter. They are the FDA telling specific companies, in writing, that they are presenting prescription drugs improperly. And the pattern across 2026 shows this is a sector under active enforcement rather than one company being singled out.

A separate and more serious category: watch for providers advertising drugs that are not approved at all. Retatrutide is an Eli Lilly investigational triple agonist still in Phase 3 trials — Lilly stated on July 23, 2026 that it intends to file for approval in Q1 2027. It is not FDA-approved for any use and it is not on the FDA's 503A bulk drug substances list, which is the specific legal reason a compounding pharmacy cannot make it. We found it named on at least one telehealth provider's site with no investigational-status disclaimer. If you see retatrutide offered for sale, that is not an early-access opportunity.

You can check any company yourself in about two minutes. The FDA maintains a public, searchable warning letter database — search the company name. In a market where nearly every quality claim is self-reported by the seller, the warning letter database is one of the very few sources that is neither marketing nor a review site. We run this check on every provider we review, and we tell you what we find either way.

The Price Difference, Honestly Stated

The economics are the entire reason this market exists, so here they are without varnish. Figures from our provider research, current to August 2026.

Option | Typical monthly cost | FDA-approved?
Brand-name with insurance coverage | $25–$50 | Yes
Medicare Part D bridge programs | ~$50 | Yes
Compounded, all-inclusive entry tier | $99–$159 | No
Compounded at maintenance dose | $199–$299 | No
Zepbound cash-pay via LillyDirect | from $349 | Yes
Wegovy cash-pay via telehealth | from $650 | Yes
Ozempic / Mounjaro cash-pay | ~$1,100 | Yes
Wegovy at full retail | up to $1,599 | Yes

Notice what sits at the top of that table. The cheapest option on the entire list is an FDA-approved brand-name drug — if your insurance covers it. Many people shopping compounded GLP-1s have never checked their own plan's weight-loss medication coverage, or checked once during the shortage era and never again. That single phone call is the highest-value step in this whole process, and it is free.

Manufacturer direct-pay programmes have also narrowed the gap substantially. Zepbound through LillyDirect starts around $349/month cash-pay — well below the $650–$1,100 telehealth brand pricing and within reach of the upper end of compounded maintenance costs. If the price difference between compounded and brand-name is the only thing pushing you toward compounded, price the manufacturer's own direct channel before deciding.

How to Choose, Practically

Choose brand-name if: Your insurance covers it — this is the cheapest and best-evidenced route and it is not close. Or you are Medicare Part D eligible and can access a bridge programme at around $50/month. Or you can afford LillyDirect's cash-pay Zepbound at around $349. Or you have a complex medical history where an FDA-reviewed manufacturing standard and a known, consistent formulation matter more than the price gap. Compounded is a reasonable choice if: You have no coverage, cannot afford $349–$650 a month, and would otherwise go untreated — which describes a great many people, and is not a trivial consideration. Obesity is a chronic disease with real consequences, and "no treatment" is not a neutral outcome. If that is your situation, choose carefully rather than cheaply. If you go compounded, these are the questions that separate a good provider from a bad one:

Which pharmacy fills my prescription, and is it 503A or 503B? A provider that will not name it has failed the most basic transparency test.
What is the individual clinical basis for compounding this for me, now that the shortages have resolved?
Has this company received an FDA warning letter? Check the FDA database yourself — do not take the company's word.
Will I speak to a clinician, or is this a questionnaire? Some providers require monthly follow-ups; others use a three-minute form with no video visit.
What is the total cost at maintenance dose, not the introductory rate? Most compounders price by dose, so the cost rises as you titrate up.
What is the refund policy once the medication ships? Usually nothing — which is normal for dispensed drugs, but you should know before ordering.
Is a certificate of analysis available for my batch? Some compounders provide one; most telehealth intermediaries do not.

Two things that should stop you regardless of price: a provider offering a drug that is not FDA-approved for any indication (retatrutide being the current example), and a provider who will not tell you which pharmacy is making your medication. Neither is a pricing question. Both are about whether anyone is accountable for what is in the vial.

Frequently Asked Questions

Is compounded semaglutide FDA-approved? No. The FDA does not review compounded drugs for safety, effectiveness or manufacturing quality before they reach patients. A compounded preparation containing semaglutide is not a generic of Wegovy or Ozempic and has not been shown to be therapeutically equivalent. Is compounded semaglutide legal? Compounding itself is legal and long-established. What changed is the basis. During the shortages, compounders could make copies of these drugs. Tirzepatide left the shortage list in October 2024 and semaglutide in early 2025. Lawful 503A compounding now requires a documented clinical reason specific to the individual patient rather than a shortage. Is compounded semaglutide the same drug as Wegovy? It contains the same active ingredient. It is not the same product. Wegovy is manufactured to an FDA-reviewed specification in an FDA-inspected facility; a compounded preparation is made by a pharmacy without that review. Formulation, concentration and excipients can differ. What is the difference between 503A and 503B? 503A pharmacies compound for an individual patient against a specific prescription and are regulated by state boards of pharmacy. 503B outsourcing facilities are FDA-registered, subject to federal cGMP standards and FDA inspection, and can compound in bulk. Most telehealth GLP-1 prescriptions are filled by 503A pharmacies. Neither produces an FDA-approved drug. Why is compounded so much cheaper? No clinical trial programme, no FDA approval process, no brand pricing, and generally cheaper active pharmaceutical ingredient sourcing. You are buying a different regulatory category of product, not the same product at a discount. Have any GLP-1 telehealth companies been warned by the FDA? Yes, several in 2026. We verified warning letter 721816 to Ivim Services LLC on February 20, 2026 finding its compounded semaglutide and tirzepatide misbranded, plus letters to FITISH and Medica Weight Loss on June 8, 2026. These concern marketing and labelling, not findings of patient harm. What about retatrutide, or other drugs I have not heard of? Retatrutide is not FDA-approved for any use. It is in Phase 3 trials, Lilly said in July 2026 it plans to file for approval in Q1 2027, and it is not on the FDA's 503A bulk substances list — meaning it cannot lawfully be compounded. Any offer to sell it should be treated as a serious warning sign about the seller. Should I switch from compounded to brand-name? That is a clinical decision for your prescriber, not a purchasing one — dosing is not always directly interchangeable between a compounded preparation and a commercial pen. Do not switch on your own. Raise it at a visit. What if I cannot afford brand-name and have no insurance? Check three things before defaulting to compounded: your plan's actual coverage (many people have not checked since the shortage era), manufacturer direct-pay such as LillyDirect Zepbound from around $349/month, and manufacturer patient assistance programmes. If compounded is still the only viable route, use the seven questions above to choose a provider.

The Bottom Line

The ten-fold price gap between compounded and brand-name GLP-1s is real, and so is the reason for it. Brand-name Wegovy and Zepbound are FDA-approved: reviewed for safety and effectiveness, manufactured under federal cGMP rules in inspected facilities, and supported by the clinical trial programmes that established these drugs work. Compounded semaglutide and tirzepatide are not FDA-approved — not reviewed for safety, effectiveness or manufacturing quality before reaching you, and not generic equivalents of anything. The legal ground shifted and much of the marketing has not caught up. Tirzepatide left the FDA shortage list in October 2024, semaglutide in early 2025. The blanket permission to compound copies during a shortage went with them. Lawful compounding now rests on a documented clinical reason specific to you — and we have documented providers in 2026 still explaining their offerings by reference to shortages that ended two years ago. The FDA is enforcing. Warning letter 721816 to Ivím on February 20, 2026 found its compounded semaglutide and tirzepatide misbranded; FITISH and Medica Weight Loss received letters in June. These are labelling and marketing actions, not findings of harm — but they are the regulator putting specific companies on notice in writing, and you can check any company yourself in the FDA's public database. None of this makes compounded GLP-1s indefensible. For someone with no insurance who cannot afford $650 a month, the realistic alternative is often no treatment at all, and obesity is a chronic disease with real consequences. That is a legitimate reason to choose a compounded product with clear eyes. But check the cheapest option first, because it is probably brand-name. If your insurance covers Wegovy or Zepbound you are likely looking at $25 to $50 a month for an FDA-approved drug — cheaper than nearly every compounded programme, with an evidence base they do not have. Medicare Part D members should ask about bridge programmes at around $50. LillyDirect's cash-pay Zepbound starts around $349. Many people shopping compounded medication have never made that phone call, or made it during the shortage and never again. And if you do go compounded, ask two questions that have nothing to do with price: which pharmacy is making this, and what is the clinical basis for compounding it for me. A provider that answers both is one worth considering. A provider that answers neither is selling you a vial with nobody's name on it. We are not healthcare professionals and this is not medical advice. Compounded drugs are not FDA-approved. Do not start, stop or switch any prescription medication based on a review — that is a decision for your prescribing clinician. GLP-1 receptor agonists are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Prices and regulatory status verified August 2026 and change frequently. This is an affiliate marketing website; see our [disclosure](/disclosure).

Sources & References

Medical Disclaimer

This article is for informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before making decisions about your health or medications. Individual experiences may vary.

Cheapest GLP-1 Programs: What the Advertised Price Actually Buys

Ivím Health Review: The February 2026 FDA Warning Letter

Best Online GLP-1 Programs: Our Investigation

Back to All Articles

Enter to Win a $1,788 CoreAge Rx Gift Card

Enter for a chance to use it toward eligible CoreAge Rx products and services.

The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.